67 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … to opioid stacking on IV tramadol relative to an approved opioid analgesic. We announced in April 2023 that the Company received official meeting
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic … of respiratory depression related to opioid stacking on IV tramadol relative to an approved opioid analgesic. We announced in April 2023 that the Company received
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
of acute post-operative pain in a medically supervised setting. The final non-inferiority study is designed to assess the theoretical risk of opioid … -induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine. The study will randomize approximately 300 post
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … with the FDA in March 2023 to discuss a proposed study protocol to assess the risk of respiratory depression related to opioid stacking on IV tramadol
8-K
EX-99.1
2yd9 skhp0g3oq
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B4
nbj3 mw8z
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
t6vhom1v oh
5 Oct 23
Free writing prospectus
5:05pm
FWP
unpue qrl3peszhf
3 Oct 23
Free writing prospectus
5:47pm
8-K
EX-99.1
5asw9d3h3v uhk
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
424B3
s02y3j63hzssnil86fnc
28 Jun 23
Prospectus supplement
4:56pm
8-K
EX-99.1
thowgts t8oxej
12 May 23
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:35am